The FDA has approved mFlusiva, the first influenza vaccine built on mRNA technology to reach the US market, for adults 50 and older. The two age groups covered by that approval were cleared on different terms, and the distinction matters for anyone deciding what to do this fall.
For adults 50 to 64, the vaccine received standard approval based on efficacy. For adults 65 and older, the FDA granted accelerated approval based on antibody response, contingent on Moderna completing a confirmatory postmarketing trial that will run across two flu seasons.
MedicalDaily previously covered the advisory committee review of the vaccine in June, when the panel voted unanimously to recommend it for adults 50 and older. The development now is the decision itself and the conditions attached to it.
The Manufacturing Difference Behind the Platform
Conventional flu vaccines are largely produced by growing influenza virus in fertilized chicken eggs, then inactivating and purifying the viral proteins that go into the shot. Cell-based and recombinant versions use different production systems but still deliver protein antigens directly.
An mRNA vaccine delivers genetic instructions instead. The body's own cells read the messenger RNA and manufacture the influenza surface protein, which the immune system then responds to.
The practical consequence is speed. Moderna says mFlusiva requires only two to three months from strain selection to rollout, against roughly six months for egg-based production. A compressed production window means strains can be chosen closer to the season, improving the odds the vaccine matches what is actually circulating.
Egg-based production also introduces egg adaptation, in which the virus acquires mutations while growing in eggs that can leave the resulting vaccine a poorer match for circulating strains. Skipping virus growth avoids that.
What none of this establishes is a mechanism for updating a vaccine mid-season. Strain selection currently happens months before flu season begins, and a mismatch discovered afterward cannot be corrected within the existing regulatory and distribution system. Faster manufacturing makes that conceivable rather than available.
The Trial Evidence and the Dispute Over the Comparator
Approval for the younger group rested on a phase 3 trial enrolling more than 40,000 adults 50 and older across 11 countries during the 2024 to 2025 respiratory season, a size and design that gives the efficacy result substantial weight. The vaccine was about 27% more effective than a licensed standard-dose flu vaccine at preventing influenza, with the precise figure reported as 26.6%.
The complication concerns older adults. The CDC recommends high-dose or adjuvanted vaccines for people 65 and older. Moderna submitted separate late-stage data showing its vaccine generated stronger antibody responses than an existing high-dose flu vaccine in that group, but antibody response is not the same as demonstrated prevention of illness, which is why the approval there is accelerated and conditional.
The regulatory path was contentious. The FDA initially declined to review the application, and Moderna subsequently revised it to seek full approval for adults 50 to 64 and accelerated approval for those 65 and older while agreeing to conduct an additional study. Agency reviewers had noted gaps in the evidence for the older group even as the advisory committee supported use there.
The Population This Approval Targets
Adults 65 and older accounted for 57% of influenza hospitalizations and 71% of deaths in the 2024 to 2025 US season, which is why this age group is where flu vaccine questions carry the most weight.
It is also the group for which the evidence supporting this particular approval is thinnest. The efficacy trial enrolled adults 50 and older, but the accelerated approval for the oldest group rests on antibody measurements, and the confirmatory trial has not been completed.
Higher reactogenicity is a further consideration in that population. Injection-site pain, fatigue, headache, joint pain and muscle aches were reported, and while those effects were characterized as manageable and consistent with other mRNA vaccines, they were more frequent than with comparators. Older adults managing multiple conditions may weigh them differently than younger patients. No new or serious safety concerns were identified by Moderna or FDA reviewers.
None of that argues against the vaccine. It argues for treating the two approved age bands as genuinely different situations rather than one indication.
The Steps Between Approval and a Shot in an Arm
Approval is not availability, and three things stand between the two.
Supply is the first. Moderna has said it expects the vaccine at select retailers ahead of the 2026 to 2027 respiratory virus season, and that it should reach eligible populations for that season. It enters a market already served by established high-dose and adjuvanted products from several manufacturers.
Recommendation is the second. The Advisory Committee on Immunization Practices, not the FDA, sets the recommendations that shape what providers stock and offer. That process runs separately from approval, and its timing is uncertain. Health and Human Services Secretary Robert F. Kennedy Jr., who oversees the agencies involved, is a critic of mRNA technology and last year oversaw the cancellation of roughly $500 million in mRNA vaccine research funding.
Coverage is the third and follows from the second. Insurance coverage without cost sharing generally tracks ACIP recommendations, so a gap between approval and recommendation can mean out-of-pocket cost in the interim.
The practical guidance is straightforward: nobody should delay flu vaccination waiting for this product. Other brands have already begun arriving in pharmacies ahead of the fall season, and multiple options are available now, including three specifically recommended for people 65 and older. Getting vaccinated on schedule matters considerably more than which product is used. Anyone interested in mFlusiva specifically can ask a pharmacist whether it has been ordered locally and what it would cost before a recommendation is issued. MedicalDaily also maintains a guide to finding low-cost vaccination locally.
Key Questions Answered
Who is the vaccine approved for? Adults 50 and older. Adults 50 to 64 received standard approval based on efficacy data. Adults 65 and older received accelerated approval based on antibody response, contingent on a confirmatory trial running across two flu seasons.
How does an mRNA flu vaccine differ from a conventional one? Conventional flu shots are largely produced by growing virus in eggs and delivering purified viral proteins. An mRNA vaccine delivers genetic instructions, and the body's own cells make the influenza protein the immune system responds to.
What advantage does that offer? Speed. Moderna says the vaccine takes two to three months from strain selection to rollout, against roughly six months for egg-based production, which allows strain choices closer to the season and avoids egg adaptation.
How effective was it? About 27% more effective than a licensed standard-dose flu vaccine in a trial of more than 40,000 adults 50 and older across 11 countries during the 2024 to 2025 season.
Why is the older-adult approval conditional? Because it rests on antibody response rather than demonstrated prevention of illness. Moderna showed stronger antibody responses than an existing high-dose vaccine, and a postmarketing trial must confirm clinical benefit.
When will it be available? Moderna expects supply at select retailers ahead of the 2026 to 2027 season. An ACIP recommendation, which shapes stocking and insurance coverage, has separate and uncertain timing.
Should anyone wait for it? No. Multiple flu vaccines are available now, including three specifically recommended for adults 65 and older. Getting vaccinated on schedule matters more than which product is used.
